

Kardiovaskularne bolesti u trudnoći: najvažnije poruke novih smjernica

Cardiovascular diseases in pregnancy: the most important messages of the new guidelines

Diana Delić-Brkljačić*

Klinički bolnički centar Sestre milosrdnice, Zagreb, Hrvatska

University Hospital Centre „Sestre milosrdnice“, Zagreb, Croatia

KLJUČNE RIJEČI: kardiovaskularne bolesti, trudnoća, smjernice.

KEYWORDS: cardiovascular diseases, pregnancy, guidelines.

CITATION: *Cardiol Croat.* 2018;13(11-12):384. | <https://doi.org/10.15836/ccar2018.384>

***ADDRESS FOR CORRESPONDENCE:** Diana Delić-Brkljačić, Klinički bolnički centar Sestre milosrdnice, Vinogradska cesta 29, HR-10000, Zagreb, Croatia. / Phone: +385-1-3787-617 / E-mail: diana.delic.brkljadic@kbcsm.hr

ORCID: Diana Delić-Brkljačić, <https://orcid.org/0000-0002-7116-2360>

Pregled ključnih poruka novih Smjernica Europskog kardiološkog društva (ESC) za liječenje kardiovaskularnih bolesti tijekom trudnoće.¹ Nove Smjernice ESC-a za liječenje kardiovaskularnih bolesti tijekom trudnoće preporučuju modificiranu klasifikaciju rizika majke Svjetske zdravstvene organizacije. U farmakološkoj terapiji, više se ne preporuča korištenje FDA (*Food and Drug Administration*) kategorija A-X za procjenu embrionalnog i fetalnog rizika. Također postoje promjene u antiaritmjskoj terapiji, kao i antikoagulantnoj i trombolitičkoj terapiji tijekom trudnoće. Provedene su promjene u vezi s vremenom intervencije kod valvularnih bolesti, kao i u dijagnostici tromboze dubokih vena u trudnica. Došlo je do nekoliko izmjena u vezi s upravljanjem hipertenzijom. Uveden je pojam interdisciplinarnog tima za bolesti srca tijekom trudnoće.

A review of the key points of the new European Society of Cardiology (ESC) guidelines for the treatment of cardiovascular disease during pregnancy.¹ The new ESC guidelines for the treatment of cardiovascular disease during pregnancy recommend the modified World Health Organization classification of maternal risk. In pharmacological therapy, decision making based on Food and Drug Administration (FDA) drugs in pregnancy categories A-X is no longer recommended. There are also changes in antiarrhythmic therapy as well as anticoagulation and thrombolytic therapy during pregnancy. Changes were made regarding timing of intervention in valvular disease and also in diagnostics of deep vein thrombosis in pregnant women. A few changes have been made regarding the management of hypertension and the pregnancy heart team is introduced.

RECEIVED:
October 27, 2018

ACCEPTED:
November 5, 2018



LITERATURE

1. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cifková R, De Bonis M, et al; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. *Eur Heart J.* 2018 Sep 7;39(34):3165-3241. <https://doi.org/10.1093/eurheartj/ehy340>